Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | IL6ST | P40189 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898645 | 1.00 | PPARA (0.43) | PPARAFAAHPPARGDAGLAACE | |
| SCHEMBL18255502 | 0.91 | PPARA (0.43) | PPARAFAAHPPARGDAGLAACE | |
| SCHEMBL14282189 | 0.86 | PPARA (0.44) | PPARAFAAHPPARGACENAAA | |
| SCHEMBL132736 | 0.81 | PPARA (0.47) | PPARAFAAHPPARGACENAAA | |
| SCHEMBL132735 | 0.81 | PPARA (0.47) | PPARAFAAHPPARGACENAAA | |
| SCHEMBL16898181 | 0.81 | PPARA (0.45) | PPARAFAAHPPARGACENAAA | |
| SCHEMBL21498426 | 0.81 | PPARA (0.45) | PPARAFAAHPPARGDAGLAACE | |
| SCHEMBL16898433 | 0.79 | CTRC (0.39) | — | |
| SCHEMBL16898430 | 0.79 | CTRC (0.39) | — | |
| SCHEMBL8811308 | 0.79 | PPARA (0.46) | PPARAFAAHPPARGNAAAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | PPARA 2291/4885FAAH 628/4885PPARG 3490/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | PPARA 2291/4885FAAH 628/4885PPARG 3490/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | PPARA 2291/4885FAAH 628/4885PPARG 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.